Menu

Top Stories

Published on Tuesday, January 8, 2019

Shire is now part of Takeda

Shire is now part of Takeda

Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in Japan. 
 
Takeda, the largest pharmaceutical company in Asia and one of the top 10 largest pharmaceutical companies in the world, now has an expanded geographic footprint and leading positions in Japan and the United States, with the acquisition of the global specialty biopharmaceutical company, Shire, headquartered in the United Kingdom and with an operational base in the United States. 

Takeda now has an extended reach, bringing medicines to more than 80 countries and regions worldwide. The combined company enables them to deliver highly-innovative medicines and transformative care to more people around the world than ever before. Their R&D efforts are now focused on four therapeutic areas— Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases, with some specific R&D investment also committed to Plasma-Derived Therapies and Vaccines. 

The Alpha-1 Foundation congratulates Takeda in this new venture to enable the delivery of highly-innovative medicines and transformative care to more patients around the world, including the rare disease patient community, such as those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1).

To learn more, please click here.


Print

The Annual Alpha-1 National Conference: The largest gathering of Alphas

Tuesday, June 18, 2019
The city of Orlando, Florida, will be the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community at large, to date, as the Alpha-1 Foundation holds its 28th Annual...
Divider

CSL Behring initiates voluntary recall for 4 lots of Zemaira

Thursday, June 6, 2019
The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency...
Divider

Here’s the “Scoop” on the Iowa Walk

Tuesday, June 4, 2019
Filled with families, friends, laughter and of course, ice cream, the Iowa Alpha-1 Get the Scoop Walk is one not to be missed. Like most walks, it was started with a small group, and now, 11 years later, this walk has become one of the most...
Divider

Alpha-1 Hero Walk raises funds and awareness for Alpha-1

Thursday, May 23, 2019
The 9th Annual Alpha-1 Hero Walk took place on May 4th, in Richmond, VA, where 75 attendees walked to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1) research and related programs, exceeding $11,000. Pamela VanScoy, Walk...
Divider

Alpha-1 Foundation celebrates the 2019 research grants

Tuesday, May 21, 2019
The Alpha-1 Foundation (A1F) hosted a reception on Monday, May 20, 2019, to honor the newly awarded research grant recipients, where 158 guests joined at the Perot Museum in Dallas, Texas, in conjunction with the 2019 American Thoracic...
Divider

New method could help find potential treatments for rare diseases

Monday, May 20, 2019
Finding treatments for rare diseases is difficult: because they affect such a small number of people, research funding and other resources may be limited. Even if researchers are interested in studying a rare disease, the methods for testing...
Divider

Celebration of Life 2019: “Alpha-1 Derby: Betting on the cure”

Friday, May 10, 2019
On Monday, April 29th, the Alpha-1 Foundation welcomed friends, family, physicians, researchers, and industry partners to the 19th Annual Celebration of Life, the Foundation’s signature fundraising event in Miami Beach, Florida. The event is...
Divider

Funding for NIH increased after House Appropriations Committee approves funding bill

Friday, May 10, 2019
The House Appropriations Committee approved the fiscal year 2020 Labor, Health and Human Services, Education, and Related Agencies bill, on Wednesday, May 8, 2019. The legislation includes funding for programs within the Departments of Labor,...
Divider

NORD releases principles to lower the cost of prescription drugs

Wednesday, May 8, 2019
The National Organization for Rare Disorders (NORD), which represents the 25-30 million Americans living with rare disorders, including Alpha-1 Antitrypsin Deficiency (Alpha-1), announced its development of key drug pricing principles,...
Divider

Alpha-1 Foundation attends Coalition of Patient Advocacy Groups (CPAG) Meeting

Tuesday, May 7, 2019
The Alpha-1 community was well represented as the Alpha-1 Foundation attended the Coalition of Patient Advocacy Groups (CPAG) Meeting, in Rockville, MD, on April 30, 2019. Photo (left to right): Jamie Sullivan, COPD Foundation; David Fernandez,...
Divider

FDA approves new, larger vial sizes for Alpha-1 augmentation therapy

Thursday, April 25, 2019
The U.S. Food and Drug Administration (FDA) has approved single-vial dosing (4-gram and 5-gram vial sizes) for ZEMAIRA® [Alpha1-Proteinase Inhibitor] for augmentation therapy, the current treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1)...
Divider

Alpha-1 Foundation co-sponsors congressional reception for the NHLBI Division of Lung Diseases

Wednesday, April 17, 2019
On April 9, 2019, the Alpha-1 Foundation was proud to be a co-sponsor of the congressional reception to celebrate the 50th anniversary of the Division of Lung Diseases of the National Heart, Lung and Blood Institute (NHLBI), an institute of the...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive